About Achilles TherapeuticsAchilles intends to develop next-generation personalized vaccines and adoptive T cell therapies for metastatic cancer by targeting truncal tumor neoantigens. The company is based on research at University College London, Cancer Research UK (CRUK) and the Francis Crick Institute.
Scientific Founder: Charles Swanton
CEO: Chris Ashton
66 articles about Achilles Therapeutics
Dr Dangl joins Achilles from Medigene AG where he spent three years as Senior Vice President for Research and Non-clinical Development.
Achilles Therapeutics (“Achilles””), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical Trial Application (CTA) to conduct a Phase I/II study with its lead product, a tumour-derived T cell therapy targeting clonal neoantigens, in development for the treatment of advanced Non-Small Cell Lung Cancer (NSCLC), has been approved by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).
Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer
Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer immunotherapies, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors.
Achilles To Support A Natural History Study Of C3 Glomerulopathy, A Rare Renal Disorder, Conducted By Experts At Imperial College London